Merial Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: November 17, 2014
Pages: 22
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M08684C29C4EN
Leaflet:

Download PDF Leaflet

Merial Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Merial Limited (Merial) is an animal healthcare company. It conducts research, and develops, manufactures and distributes pharmaceutical products and vaccines. The company offers products for dogs, cats, avian, swine, cows, equine, and veterinary public health. Merial markets its products through its brands IVOMEC, HEARTGARD, FRONTLINE and FRONTLINE Plus. The company operates a network of research and development centers, and manufacturing sites. It has its presence in more than 150 countries worldwide. The company operates as a subsidiary of Sanofi. Merial Limited is headquartered in Duluth, Georgia, the US. The company plans to expand its operations in India. Merial Is headquartered in Georgia, the US.

Merial Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Merial Limited, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
SCYNEXIS Secures US$13.5 Million In Series C-2 Financing
Licensing Agreements
Vivalis Enters Into Licensing Agreement With Merial For EB66 Cell Line
GenVec Enters Into Licensing Agreement With Merial For Vaccine Technology
Centegen Enters Into Licensing Agreement With Merial For CEN-102
Vivalis Enters Into Licensing Agreement With Merial For EB66 Cell Line
A.P. Pharma Enters Into Licensing Agreement With Merial
Merial Enters Into Licensing Agreement With Scarab Genomics For Clean Genome E. coli
Imugene Enters Into Licensing Agreement With Merial For Vector Technology
Merial Limited - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Merial Limited, Pharmaceuticals & Healthcare, Key Facts
Merial Limited, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Merial Limited, Deals By Therapy Area, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
SCYNEXIS Secures US$13.5 Million In Series C-2 Financing
Vivalis Enters Into Licensing Agreement With Merial For EB66 Cell Line
GenVec Enters Into Licensing Agreement With Merial For Vaccine Technology
Centegen Enters Into Licensing Agreement With Merial For CEN-102
Vivalis Enters Into Licensing Agreement With Merial For EB66 Cell Line
A.P. Pharma Enters Into Licensing Agreement With Merial
Merial Enters Into Licensing Agreement With Scarab Genomics For Clean Genome E. coli
Imugene Enters Into Licensing Agreement With Merial For Vector Technology
Merial Limited, Key Competitors
Merial Limited, Key Employees

LIST OF FIGURES

Merial Limited, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Merial Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Skip to top


Ask Your Question

Merial Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: